EC Nutrition

Editorial Volume 18 Issue 10 - 2023

A Pharmaconutritional Strategy to Reverse BPH

Paul Clayton*

Visiting Professor, Department Preventative and Personal Medicine, Institute of Interdisciplinary Medicine, Moscow, Russia

*Corresponding Author: Paul Clayton, Visiting Professor, Department Preventative and Personal Medicine, Institute of Interdisciplinary Medicine, Moscow, Russia.
Received:October 31, 2023; Published: November 24, 2023



Benign prostatic hyperplasia (BPH) has become very common in ageing males. Like so many other chronic disorders it is increasing, with a near-doubling in the last 2 decades [1,2]. And as with the case of so many other chronic disorders, that increase is obviously due to our unhealthy diet and lifestyle because BPH hardly occurs in vestigial groups [3].

  1. Launer BM., et al. “The rising worldwide impact of benign prostatic hyperplasia”. BJU International 6 (2021): 722-728.
  2. GBD 2019 Benign Prostatic Hyperplasia Collaborators. “The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019”. The Lancet Healthy Longevity 11 (2022): e754-e776.
  3. Trumble BC., et al. “Challenging the inevitability of prostate enlargement: low levels of benign prostatic hyperplasia among tsimane forager-horticulturalists”. Journals of Gerontology Series A-Biological Sciences and Medical Sciences 10 (2015): 1262-1268.
  4. Herman-Giddens ME., et al. “Secondary sexual characteristics in boys: data from the Pediatric Research in Office Settings Network”. Pediatrics 5 (2012): e1058-e1068.
  5. Akanni OO., et al. “Protocatechuic acid ameliorates testosterone-induced benign prostatic hyperplasia through the regulation of inflammation and oxidative stress in castrated rats”. Journal of Biochemical and Molecular Toxicology 8 (2020): e22502.
  6. Vignozzi L., et al. “Benign prostatic hyperplasia: a new metabolic disease?” Journal of Endocrinological Investigation4 (2014): 313-322.
  7. Vikram A., et al. “Insulin-resistance and benign prostatic hyperplasia: the connection”. European Journal of Pharmacology 2-3 (2010): 75-81.
  8. Hellwege JN., et al. “Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network”. Scientific Reports 1 (2019): 6077.
  9. Mohammad S and Thiemermann C. “Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions”. Frontiers in Immunology 11 (2021): 594150.
  10. Cani PD., et al. “Metabolic endotoxemia initiates obesity and insulin resistance”. Diabetes7 (2007): 1761-1772.
  11. Liu Y., et al. “Curcumin attenuates prostatic hyperplasia caused by inflammation via up-regulation of bone morphogenetic protein and activin membrane-bound inhibitor”. Pharmaceutical Biology 1 (2021): 1026-1035.
  12. Pang J., et al. “Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease”. Alimentary Pharmacology and Therapeutics 2 (2017): 175-182.
  13. Bugianesi E., et al. “Insulin resistance in nonalcoholic fatty liver disease”. Current Pharmaceutical Design 17 (2010): 1941-1951.
  14. Riazi K., et al. “The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis”. The Lancet Gastroenterology and Hepatology 9 (2022): 851-861.
  15. Chung GE., et al. “Nonalcoholic fatty liver disease is associated with benign prostate hyperplasia”. Journal of Korean Medical Science 22 (2020): e164.
  16. Chughtai B., et al. “Role of inflammation in benign prostatic hyperplasia”. Nature Reviews Urology 3 (2011): 147-150.
  17. Kyprianou N., et al. “Apoptotic versus proliferative activities in human benign prostatic hyperplasia”. Human Pathology 7 (1996): 668-675.
  18. Chand HS., et al. “IL-13 in LPS-induced inflammation causes Bcl-2 expression to sustain hyperplastic mucous cells”. Scientific Reports 1 (2018): 436.
  19. Smith KR., et al. “Inflammation, mucous cell metaplasia, and Bcl-2 expression in response to inhaled lipopolysaccharide aerosol and effect of rolipram”. Toxicology and Applied Pharmacology 3 (2011): 253-260.
  20. Gressner AM., et al. “Roles of TGF-beta in hepatic fibrosis”. Frontiers in Bioscience 7 (2002): d793-807.
  21. Border WA and Noble NA. “Transforming growth factor beta in tissue fibrosis”. The New England Journal of Medicine 331 (1994): 1286-1292.
  22. Ehnert S., et al. “TGF-β1 as possible link between loss of bone mineral density and chronic inflammation”. PLoS One 11 (2010): e14073.
  23. Vilahur G., et al. “Phytosterols and Inflammation”. Current Medicinal Chemistry 37 (2019): 6724-6734.
  24. Sultan C., et al. “Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts”. The Journal of Steroid Biochemistry and Molecular Biology 20 (1984): 515-519.
  25. Ghadian A and Rezaei M. “Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)”. Inflammopharmacology 4 (2017): 451-458.
  26. Liu Y., et al. “Curcumin attenuates prostatic hyperplasia caused by inflammation via up-regulation of bone morphogenetic protein and activin membrane-bound inhibitor”. Pharmaceutical Biology 1 (2021): 1026-1035.
  27. Kim SK., et al. “Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model”. BMC Complementary and Alternative Medicine 15 (2015): 380-386.
  28. Zhou J., et al. “Potential ameliorative effects of epigallocatechin3gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats”. International Immunopharmacology 64 (2018): 162-169.
  29. Rho J., et al. “Asteris radix et rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation”. Journal of Ethnopharmacology 255 (2020): 112779.
  30. Raafat M., et al. “Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2”. Pharmaceuticals2 (2022): 130.
  31. Miyake M., et al. “Prostate diseases and microbiome in the prostate, gut, and urine”. Prostate International 2 (2022): 96-107.
  32. St Sauver JL., et al. “Association between prostatitis and development of benign prostatic hyperplasia”. The Journal of Urology 4 (2007): 497.
  33. Kim EY., et al. “6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis”. BMB Reports 9 (2019): 560-565.
  34. Russo GI., et al. “Relationship between dietary patterns with benign prostatic hyperplasia and erectile dysfunction: a collaborative review”. Nutrients11 (2021): 4148.

Paul Clayton. “A Pharmaconutritional Strategy to Reverse BPH”. EC Nutrition  18.10 (2023): 01-05.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net